• Increase font size
  • Default font size
  • Decrease font size

California Mesothelioma

We are here to help you

Diagnosis of Sarcomatoid Mesothelioma

The differentiation of sarcomatoid mesothelioma from other cell tumors by light microscopy is quite difficult. The role of immunohistochemistry is also not well defined in its diagnosis. Since sarcomatoid mesothelioma is not always cytokeratin-negative, the distinction between it and sarcoma is not always possible. In this context, the doctors undertook a study to investigate the utility of diagnostic immunohistochemistry for distinguishing sarcomatoid mesothelioma from its histological mimics, high-grade sarcoma and pulmonary sarcomatoid carcinoma.

 

For its study, the researchers stained the mesotheliomas with sarcomatoid components. They assessed the intensity and distribution of staining with the help of a semi quantitative scale. Only tumors with unequivocal staining were considered positive for tabulation. Then they compared the immunophenotypic profiles of these tumors with 24 high-grade sarcomas. The sarcomatoid carcinomas were also stained for thyroid transcription factor-1 (TTF-1).

 

The study showed that Cytokeratin 5/6 stained most of the epithelioids but the sarcomatoids were rarely stained. On the other hand, Calretinin and thrombomodulin each stained 70% of sarcomatoid. All 10 sarcomatoids were negative for TTF-1. This led to the conclusion that a wide immunophenotypic overlap exists among different sarcomatoids. Cytokeratin and calretinin have the most value in differentiating different sarcomatoids. Clinicopathological data, especially information about the gross appearance of the tumor is quite important for sarcomatoid tumors. Thus, it should be noted and carefully correlated with microscopic and immunohistochemical findings.

 

Cancer News

  • American Cancer Society :: News and Features 2 Mar 2010 | 10:00 pm

    Revised prostate cancer screening guidelines from the American Cancer Society offer clearer guidance on what you should discuss with your doctor before you decide whether to be tested for prostate cancer.

    Read more...
  • American Cancer Society :: News and Features 15 Feb 2010 | 10:00 pm

    A new study finds that women who take aspirin regularly after breast cancer treatment may have a lower risk of breast cancer death and recurrence. Experts caution more research is needed.

    Read more...
  • American Cancer Society :: News and Features 31 Jan 2010 | 10:00 pm

    While hormone therapy is beneficial for many men with prostate cancer, there is growing concern that it may increase heart disease risk factors, according to a new report by leading health organizations.

    Read more...

Mayo Clinic News

  • Blogs - All topics 12 Mar 2010 | 11:00 pm

    Genetic test for weight loss holds promise, but diet and exercise comes first.

    Read more...
  • MayoClinic.com Podcast 22 Dec 2009 | 11:00 pm

    Chemotherapy side effects may include thinking and short-term memory problems. Chemo brain may last for months, or longer.

    Read more...
  • MayoClinic.com Podcast 5 Aug 2009 | 11:00 pm

    It's not uncommon to have a smoking relapse when you quit smoking. Get tips to get back on track with your stop smoking plan.

    Read more...

Cancer News

  • NCI Clinical Trial Results 14 Mar 2010 | 9:00 pm

    Giving radiation therapy in fewer but larger doses may be an alternative to standard radiation therapy for some women with early-stage breast cancer, according to a study published in the February 11, 2010, New England Journal of Medicine.

    Read more...
  • NCI Clinical Trial Results 24 Feb 2010 | 10:00 pm

    Clinical trial results published online December 4, 2009, in The Lancet, show that an antidepressant and two different hormone therapies reduced the number and intensity of hot flashes in men receiving hormonal treatment for advanced prostate cancer.

    Read more...

Advertisement

Advertisement